These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28412159)

  • 1. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
    Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
    Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Tu Y; Zhu W; Luo R; Tu Q; Wang P; Wu C; Gong P; Zheng P
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1680-4. PubMed ID: 26923692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
    Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
    Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
    Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
    Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Yang Y; Zhang Y; Yang L; Zhao L; Si L; Zhang H; Liu Q; Zhou J
    Bioorg Chem; 2017 Feb; 70():126-132. PubMed ID: 28043720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.
    Zhang L; Zhang B; Zhao J; Zhi Y; Wang L; Lu T; Chen Y
    Eur J Med Chem; 2017 Sep; 138():942-951. PubMed ID: 28755635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel [1,2,4] Triazol [4,3-a] Pyridine Derivatives as Potential Selective c-Met Inhibitors with Improved Pharmacokinetic Properties.
    Zhao J; Gou S; Zhang X; Liang Y; Fang L
    Anticancer Agents Med Chem; 2017; 17(8):1102-1112. PubMed ID: 27804848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
    Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
    Wu K; Ai J; Liu Q; Chen T; Zhao A; Peng X; Wang Y; Ji Y; Yao Q; Xu Y; Geng M; Zhang A
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6368-72. PubMed ID: 22985853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
    Liu TC; Peng X; Ma YC; Ji YC; Chen DQ; Zheng MY; Zhao DM; Cheng MS; Geng MY; Shen JK; Ai J; Xiong B
    Acta Pharmacol Sin; 2016 May; 37(5):698-707. PubMed ID: 27041462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.